Per-protocol analyses of pragmatic trials

New England Journal of Medicine

Volumn 377, Issue 14, 2017, Pages 1391-1398

  Hernán, Miguel A ^a,b   Robins, James M ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; ARTICLE; CONFOUNDING VARIABLE; DATA ANALYSIS; DATA COLLECTION METHOD; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; PATIENT COMPLIANCE; PER PROTOCOL ANALYSIS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELECTION BIAS; STATISTICAL ANALYSIS; SYSTEMATIC ERROR; TREATMENT OUTCOME; CLINICAL PROTOCOL; METHODOLOGY; PROCEDURES;

CLINICAL PROTOCOLS; DATA INTERPRETATION, STATISTICAL; HUMANS; INTENTION TO TREAT ANALYSIS; PATIENT COMPLIANCE; PRAGMATIC CLINICAL TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 85030629082     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsm1605385     Document Type: Article

References (31)

1. Sheiner LB, Rubin DB. Intention-to-treat analysis and the goals of clinical trials. Clin Pharmacol Ther 1995;57:6-15.
2. Gupta SK. Intention-to-treat concept: a review. Perspect Clin Res 2011;2:109-12.
3. Piantadosi S. Clinical trials: a methodologic perspective, 2nd ed. Hoboken, NJ: Wiley-Interscience, 2005.
4. Hernán MA, Hernández-Díaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials 2012;9: 48-55.
5. Goetghebeur E, Loeys T. Beyond intention to treat. Epidemiol Rev 2002;24:85-90.
6. Little RJ, D’Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012; 367:1355-60.
7. Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 2000;56:779-88.
8. Dunn G, Goetghebeur E. Analysing compliance in clinical trials. Stat Methods Med Res 2005;14:325-6.
9. The Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 1980;303:1038-41.
10. Murray EJ, Hernán MA. Adherence adjustment in the Coronary Drug Project: a call for better per-protocol effect estimates in randomized trials. Clin Trials 2016;13:372-8.
11. Robins JM. Correction for non-compliance in equivalence trials. Stat Med 1998;17:269-302.
12. Hernán MA, Robins JM. Causal inference. Boca Raton, FL: Chapman & Hall/CRC (in press).
13. Robins JM. A new approach to causal inference in mortality studies with a sustained exposure period — application to the healthy worker survivor effect. Math Model 1986;7:1393-512.
14. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-60.
15. Hernán MA, Cole SR, Margolick J, Robins JM. Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiol Drug Saf 2005;14:477-91.
16. Robins JM, Hernán MA. Estimation of the causal effects of time-varying exposures. In: Fitzmaurice G, Davidian M, Verbeke G, Molenberghs G, eds. Longitudinal data analysis. New York: Chapman and Hall/CRC Press, 2008:553-99.
17. Bang H, Robins JM. Doubly robust estimation in missing data and causal inference models. Biometrics 2005;61:962-73.
18. Van der Laan M, Rose S. Targeted learning: causal inference for observational and experimental data. New York: Springer, 2011.
19. Toh S, Hernández-Díaz S, Logan R, Robins JM, Hernán MA. Estimating absolute risks in the presence of nonadherence: an application to a follow-up study with baseline randomization. Epidemiology 2010;21:528-39.
20. Lodi S, Sharma S, Lundgren JD, et al. The per-protocol effect of immediate vs. deferred ART initiation in the START randomized trial. AIDS 2016;30:2659-663.
21. Holme Ø, Løberg M, Kalager M, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA 2014;312:606-15.
22. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol 2000;29:722-9.
23. Hernán MA, Robins JM. Instruments for causal inference: an epidemiologist’s dream? Epidemiology 2006;17:360-72.
24. Ten Have TR, Normand SL, Marcus SM, Brown CH, Lavori P, Duan N. Intent-to-treat vs. non-intent-to-treat analyses under treatment non-adherence in mental health randomized trials. Psychiatr Ann 2008;38:772-83.
25. Cole SR, Chu H. Effect of acyclovir on herpetic ocular recurrence using a structural nested model. Contemp Clin Trials 2005;26:300-10.
26. Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol 2012;52:275-301.
27. Ioannidis JP. Why most discovered true associations are inflated. Epidemiology 2008;19:640-8.
28. Rosenbaum PR. Observational studies. 2nd ed. New York: Springer, 2002.
29. Ding P, VanderWeele TJ. Sensitivity analysis without assumptions. Epidemiology 2016;27:368-77.
30. Swanson SA, Holme Ø, Løberg M, et al. Bounding the per-protocol effect in randomized trials: an application to colorectal cancer screening. Trials 2015;16:541.
31. Dodd S, White IR, Williamson P. Nonadherence to treatment protocol in published randomised controlled trials: a review. Trials 2012;13:84.